Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Subjects With Advanced Solid Tumors

NCT02660034 is registered in ClinicalTrials.gov with BeiGene as lead sponsor.

NCT NCT02660034
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02660034 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Subjects With Advanced Solid Tumors
Lead sponsor
BeiGene
Phase
Phase 1
Overall status
Completed
Start date
February 2, 2016
Completion date
September 9, 2020
Enrollment
229 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors